Jonathan A. Ledermann

Best original research presented at the 27th European Congress on Gynaecological Oncology: best of ESGO 2026.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: July 06, 2026

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

Journal: JAMA oncology

Published: June 25, 2026

Highlights from the 27th European Congress on Gynecological Oncology in Copenhagen: interview compilation of the ENYGO-IJGC editorial fellows.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: April 12, 2026

PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis.

Journal: JAMA network open

Published: November 05, 2025

Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: October 16, 2025

ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer.

Journal: ESMO open

Published: September 18, 2025

Mechanisms of drug resistance: PARP inhibitors, antibody-drug-conjugates, and immunotherapy.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: August 04, 2025

The PARP inhibitor/immunotherapy paradox in advanced ovarian cancer: positive endpoints, perplexing interpretations.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: July 04, 2025

Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 04, 2025

Best original research presented at the 27th European Congress on Gynaecological Oncology: best of ESGO 2026.

Best original research presented at the 27th European Congress on Gynaecological Oncology: best of ESGO 2026.

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

Highlights from the 27th European Congress on Gynecological Oncology in Copenhagen: interview compilation of the ENYGO-IJGC editorial fellows.

Highlights from the 27th European Congress on Gynecological Oncology in Copenhagen: interview compilation of the ENYGO-IJGC editorial fellows.

PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis.

PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis.

Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial.

Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial.

ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer.

ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer.

Mechanisms of drug resistance: PARP inhibitors, antibody-drug-conjugates, and immunotherapy.

Mechanisms of drug resistance: PARP inhibitors, antibody-drug-conjugates, and immunotherapy.

The PARP inhibitor/immunotherapy paradox in advanced ovarian cancer: positive endpoints, perplexing interpretations.

The PARP inhibitor/immunotherapy paradox in advanced ovarian cancer: positive endpoints, perplexing interpretations.

Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial.

Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial.

INTERLACE: not a new standard for cervical cancer chemoradiation - Authors' reply.

INTERLACE: not a new standard for cervical cancer chemoradiation - Authors' reply.

Controversies in the management of rare gynecologic cancers.

Controversies in the management of rare gynecologic cancers.

ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025.

ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025.